Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
Dublin, Oct. 29, 2026 (GLOBE NEWSWIRE) -- "Gene Writing Technology Global Market Report 2026" has been added to ResearchAndMarkets.com's offering.
The global gene writing technology market is experiencing exponential growth as advances in DNA synthesis, genome engineering and synthetic biology accelerate the development of precision medicines and biotechnology applications. The market is projected to increase from $5.62 billion in 2025 to $7 billion in 2026, representing a compound annual growth rate (CAGR) of 24.5%.
Historic market growth has been supported by improvements in chemical DNA synthesis techniques, expanding genomics research funding and rising demand for gene editing applications. Increased biopharmaceutical research activity and broader adoption of synthetic biology tools have also strengthened demand for technologies that enable the accurate design, synthesis and modification of genetic sequences.
The gene writing technology market is forecast to reach $16.97 billion by 2030, expanding at a CAGR of 24.8% from 2026. Key growth drivers include the development of gene-based therapeutics, increased automation across DNA synthesis platforms and continued investment in agricultural biotechnology. Demand is also being supported by AI-driven gene design tools and the need for scalable, cost-efficient DNA manufacturing capabilities.
Prominent gene writing technology market trends include greater adoption of enzymatic DNA synthesis, increasing demand for long-sequence DNA assembly and rising investment in synthetic biology platforms. Custom gene design services are expanding, while automated gene synthesis workflows are enabling biotechnology and pharmaceutical organizations to improve accuracy, shorten development timelines and scale research programs more efficiently.
The continued expansion of gene therapy development is expected to be a major catalyst for market growth. Progress in genetic engineering, combined with supportive regulatory frameworks, is helping more gene-based treatments advance from laboratory research into clinical trials and regulatory review. Gene writing technologies support this progress by enabling precise and programmable insertion, correction or modification of genetic material, creating opportunities for safer and more durable treatments across a broad range of inherited conditions.
Clinical activity illustrates this momentum. According to the American Society of Gene & Cell Therapy, the number of gene therapies in Phase III increased by 10% in the fourth quarter of 2023 compared with the previous quarter. This represented the first quarterly increase since the third quarter of 2022 and highlighted the expanding pipeline of late-stage gene therapy candidates.
Innovation in in vivo gene editing is also shaping the competitive landscape. In January 2026, Tessera Therapeutics announced the advancement of TSRA-196, a gene writing-based therapy targeting alpha-1 antitrypsin deficiency. The therapy is designed for intravenous administration and uses the company's proprietary lipid nanoparticle delivery system to transport RNA to liver cells.
Built on a target-primed reverse transcription platform, TSRA-196 is intended to permanently correct the underlying SERPINA1 gene mutation and potentially restore functional alpha-1 antitrypsin protein expression. The program reflects the industry's focus on developing durable genetic treatments that can address the underlying causes of disease rather than provide temporary symptomatic relief.
Strategic collaborations are further advancing gene writing technology and targeted genetic medicine. In February 2024, Intellia Therapeutics partnered with ReCode Therapeutics to develop gene editing therapies for cystic fibrosis. The collaboration combines Intellia's CRISPR-based DNA editing capabilities with ReCode's Selective Organ Targeting lipid nanoparticle delivery platform.
The partnership aims to correct cystic fibrosis-causing mutations accurately, expand options for patients with limited available therapies and accelerate the development of next-generation gene editing treatments. It also demonstrates the growing importance of combining genome editing technologies with targeted delivery systems to improve therapeutic precision and reach specific organs or cell types.
North America was the largest regional market for gene writing technology in 2025, supported by established biotechnology infrastructure, strong research investment and an active gene therapy development pipeline. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The global market covers Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa, including Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the UK, the USA, Canada, Italy and Spain.
Markets Covered:
1) By Technology: Chemical Deoxyribonucleic Acid Synthesis; Enzymatic Deoxyribonucleic Acid Synthesis
2) By Product Type: Gene Editing Tools; Gene Synthesis Platforms; Delivery Systems; Other Product Types
3) By Application: Therapeutics; Research; Agriculture; Diagnostics
4) By End-User: Pharmaceutical and Biotechnology Companies; Academic and Research Institutes; Hospitals and Clinics; Other End Users
Subsegments:
1) By Chemical Deoxyribonucleic Acid Synthesis: Solid Phase Synthesis; Liquid Phase Synthesis; Microarray Based Synthesis; Chip Based Synthesis
2) By Enzymatic Deoxyribonucleic Acid Synthesis: Polymerase Mediated Synthesis; Ligase Mediated Synthesis; Recombinase Mediated Synthesis; Template Independent Synthesis
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
Companies Featured
The companies featured in this Gene Writing Technology market report include:
For more information about this report visit https://www.researchandmarkets.com/r/qu11vz
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.